HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat is approved for the treatment of advanced primary cutaneous T-cell lymphoma [7], and belinostat is approved for the treatment of relapsed or refractory peripheral T-cell lymphoma [8]; other HDAC inhibitors are currently being investigated in clinical and pre-clinical studies.